Ivonescimab plus chemotherapy in advanced or metastatic non‑squamous non‑small cell lung cancer with EGFR variant in China: a cost-effectiveness analysis.

Transl Lung Cancer Res · 2025 · PMC12170261 · PMID 40535084

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although the current OS data is as yet immature, a favorable trend toward improved OS was noticeable in the ivonescimab group (HR 0.80, 95% CI: 0.59−1.08).

also in 907 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.